Clinical trials: Patient Preference
Rhinitis, Allergic, Perennial
Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS
The purpose of this replicate study to FFU105927 is to provide data on subject preference of FFNS as compared with FPNS.
- Trial name
- NCT00539006
- Testing
- FPNS, FFNS
- Where
- 24 sites in United States
- Volunteers
- 377 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Renal Cell
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic…
- Trial name
- PISCES (NCT01064310)
- Testing
- pazopanib, sunitinib
- Where
- 51 sites in Finland, France and 3 more
- Volunteers
- 169 people
- Sponsor
- Novartis Pharmaceuticals
Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Study to evaluate patient preference of deferasirox film-coated tablet (FCT) or deferasirox dispersible tablet (DT) in patient with transfusion - dependent thalassemia or non-transfusion -dependent thalassemia as measured by…
- Trial name
- Jupiter (NCT02993224)
- Testing
- Deferasirox dispersable tablet (DT), Deferasirox film coated tablet (FCT)
- Where
- 17 sites in Egypt, Lebanon and 5 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Dependency
Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)
This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy.
- Trial name
- NCT01075971
- Testing
- Buprenorphine hydrochloride marketed sublingual tablet (Subutex), Buprenorphine hydrochloride fast dissolving tablet (FDT)
- Volunteers
- 52 people
- Sponsor
- Indivior Inc.
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Osteoporosis, Postmenopausal
Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.
- Trial name
- NCT00405392
- Testing
- Ibandronate (SB743830HD)
- Volunteers
- 365 people
- Sponsor
- GlaxoSmithKline
Colonoscopy Preparation
2 Regimens of Lactulose for Colonoscopy Preparation in Adults
The purpose of the study is to determine the efficacy of 2 regimens of lactulose as a preparation for colonoscopy.
- Trial name
- NCT01887470
- Testing
- Full dose preparation, Split dose preparation
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Cumberland Pharmaceuticals
Allergic Rhinitis
Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).
- Trial name
- NCT05146206
- Testing
- Observational
- Where
- Australia
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Community and Patient Preference Research Pty Ltd
Vascular Access Complications
Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology
The study will test a hypothesis that the AccuCath™ System will have a higher rate of successful first attempt peripheral IV placement and higher clinician and patient satisfaction compared to Conventional IV Catheters.
- Trial name
- NCT01940354
- Testing
- AccuCath IV Catheter System, Conventional IV Catheter System
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- C. R. Bard
Ulcerative Colitis
Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)
This study is designed to determine whether ulcerative colitis participants prefer delivery of golimumab via a prefilled syringe or the Smartject™ device.
- Trial name
- SMART (NCT02155335)
- Testing
- Prefilled Syringe delivery of Golimumab, Smartject Device delivery of Golimumab
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive (COPD)
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare in COPD patients naïve to DPIs, the perception of the Breezhaler® and Ellipta® devices' feedback mechanisms evaluated using a preference questionnaire.
- Trial name
- Advantage (NCT02551224)
- Testing
- Patient preference questionnaire
- Where
- 10 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Vascular Access Complication
AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use
The study will test a hypothesis that the AccuCath™ System will have a higher rate of successful first attempt peripheral intravenous (IV) placement, higher completion of therapy, fewer complications, longer dwell times, and…
- Trial name
- NCT01943474
- Testing
- AccuCath IV Catheter Device, Conventional IV Catheter Device
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- C. R. Bard
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Calcium and Vitamin D Deficiencies
Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.
The purpose of this study is to compare the preference of Calcichew D3 500/400 (containing 500 mg calcium and 400 IU of vitamin D) with Adcal-D3 600/400 (containing 600 mg of calcium and 400 IU of vitamin D) in Test Group 1, and…
- Trial name
- NCT02457247
- Testing
- Calcichew D3, Adcal-D3, Kalcipos-D
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 276 people
- Sponsor
- Takeda
Opioid Induced Constipation
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
- Trial name
- NCT03060512
- Testing
- Polyethylene Glycol 3350, Movantik
- Where
- 53 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Breast Neoplasms
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer.
- Trial name
- PrefHER (NCT01401166)
- Testing
- Herceptin, Single-Use Injection Device
- Where
- 75 sites in Canada, Denmark and 10 more
- Volunteers
- 488 people
- Sponsor
- Hoffmann-La Roche
Rhinitis, Allergic, Perennial and Seasonal
Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays
The purpose of this study is to provide information on whether subjects with allergic rhinitis (AR) prefer the administration of fluticasone furoate (FF) nasal spray or mometasone furoate (MF) nasal spray based on how the…
- Trial name
- NCT02397915
- Testing
- FF nasal spray, MF nasal spray
- Where
- 12 sites in Argentina, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
Preference study: Genuair vs HandiHaler inhalers in COPD patients.
- Trial name
- NCT01385696
- Testing
- Genuair® (Almirall S.A.), HandiHaler® (Boehringer Ingelheim's)
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 130 people
- Sponsor
- Almirall, S.A.
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Parkinson's Disease
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home…
- Trial name
- CARE-ACT (NCT01330290)
- Testing
- Neupro®
- Where
- 54 sites in Germany
- Volunteers
- 148 people
- Sponsor
- UCB Pharma